TIRZEPATIDE.CFD is an independent information website. We do not sell, supply or prescribe any substance.
TIRZEPATIDE
.CFD
Languages
For education only. Tirzepatide is a prescription medicine in many countries; research-grade material is not a licensed product. Nothing here is medical advice.
Abstract illustration of a peptide chain binding two receptors for the tirzepatide guide
LY3298176 · DUAL INCRETIN AGONIST

Tirzepatide.
Two Hormone Signals, One Molecule

A clear, referenced overview of tirzepatide, the peptide that acts on both the GIP and GLP-1 receptors, for students, researchers and readers who want the facts behind the headlines.

Tirzepatide is authorised as a prescription-only medicine under the brand names Mounjaro and Zepbound. Research-grade tirzepatide is a different thing: it is not a licensed medicine and is intended for laboratory use only. This website is educational.
GIP + GLP-1 dual receptor agonist
Discovered by Eli Lilly and Company
First approved by the FDA in May 2022

Why Tirzepatide Matters

Tirzepatide is a synthetic peptide that activates two receptors at once: the receptor for GIP (glucose-dependent insulinotropic polypeptide) and the receptor for GLP-1 (glucagon-like peptide-1). Both hormones are released by the gut after a meal and help control blood sugar and appetite. Older medicines such as liraglutide and semaglutide act on the GLP-1 receptor only.

In large trials, tirzepatide lowered average blood sugar more than several established diabetes treatments. In adults with obesity, the highest dose reduced body weight by about 21% on average over 72 weeks. Those results turned it into one of the most studied metabolic drugs of the decade.

This site explains how the molecule works, what each major trial measured, how it came to be approved, and why the licensed medicine and research-grade peptide are treated so differently. Figures come from peer-reviewed papers, and the trial page lists them.

Please Keep in Mind

Tirzepatide.cfd offers general information and does not give medical advice. Decisions about treatment belong with a doctor who knows your medical history. Research-grade tirzepatide is sold for laboratory work only and is not meant for use in people.

Tirzepatide in Brief

Research codeLY3298176
Compound typeSynthetic peptide of 39 amino acids with a C20 fatty diacid side chain
TargetsGIP receptor and GLP-1 receptor
DeveloperEli Lilly and Company (Indianapolis, USA)
Half-lifeAbout 5 days, allowing one injection per week
Brand namesMounjaro (type 2 diabetes and weight management); Zepbound (US, weight management and sleep apnoea)
Legal statusPrescription-only medicine in the EU, UK, US and many other countries

What You Will Find Here